Delphine Maucort-Boulch
Overview
Explore the profile of Delphine Maucort-Boulch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
156
Citations
2904
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trecourt A, Rabodonirina M, Donzel M, Simon B, Mauduit C, Traverse-Glehen A, et al.
Clin Microbiol Infect
. 2025 Jan;
PMID: 39855626
Objectives: Because fungal infections (FI) are frequently encountered by pathologists, it is crucial to improve fungal diagnosis on formalin-fixed paraffin-embedded tissues (FT). We aimed to investigate if a histomolecular approach...
2.
Belkaid S, Clerc M, Amini-Adle M, Maucort-Boulch D, Dalle S, Thomas L
J Eur Acad Dermatol Venereol
. 2025 Jan;
PMID: 39760254
No abstract available.
3.
Msika A, Mathias V, Boudigou M, Chambon M, Dubois V, Hajri T, et al.
Am J Obstet Gynecol
. 2024 Oct;
PMID: 39370035
Background: Low-risk gestational trophoblastic neoplasia are currently receiving monochemotherapy as first-line therapy. In the case of a resistance, a second-line monochemotherapy or polychemotherapy is proposed. As an alternative to these...
4.
Bodinier M, Peronnet E, Llitjos J, Kreitmann L, Brengel-Pesce K, Rimmele T, et al.
Crit Care
. 2024 Jul;
28(1):240.
PMID: 39010113
Background: The immune response of critically ill patients, such as those with sepsis, severe trauma, or major surgery, is heterogeneous and dynamic, but its characterization and impact on outcomes are...
5.
Esparragosa Vazquez I, Sanson M, Chinot O, Fontanilles M, Rivoirard R, Thomas-Maisonneuve L, et al.
Neurooncol Adv
. 2024 Jun;
6(1):vdae078.
PMID: 38855053
Background: Based on preclinical studies showing that IDH-mutant (IDHm) gliomas could be vulnerable to PARP inhibition we launched a multicenter phase 2 study to test the efficacy of olaparib monotherapy...
6.
Bienvenu A, Cour M, Pavese P, Guichon C, Leray V, Chapuis C, et al.
J Antimicrob Chemother
. 2024 Apr;
79(6):1407-1412.
PMID: 38656566
Background: Invasive candidiasis is still recognized as a major cause of morbidity and mortality. To support clinicians in the optimal use of antifungals for the treatment of invasive candidiasis, a...
7.
Robert M, Poghosyan T, Maucort-Boulch D, Filippello A, Caiazzo R, Sterkers A, et al.
Lancet Diabetes Endocrinol
. 2024 Mar;
12(4):267-276.
PMID: 38452784
Background: The multicentre randomised trial YOMEGA (NCT02139813) comparing the one anastomosis gastric bypass (OAGB) with the Roux-en-Y gastric bypass (RYGB) confirmed the non-inferiority of OAGB on weight loss outcomes at...
8.
Portefaix A, Dhelens C, Recher M, Cour-Andlauer F, Naudin J, Mortamet G, et al.
Arch Dis Child
. 2024 Feb;
109(9):717-723.
PMID: 38360044
Purpose: Toxic shock syndrome (TSS) is a rare disease responsible for significant morbidity and mortality. Intravenous immunoglobulin (IG) therapy in paediatric TSS could improve shock and organ failure, but more...
9.
Savary C, Luciana L, Huchede P, Tourbez A, Coquet C, Broustal M, et al.
Cell Rep Med
. 2023 Dec;
4(12):101339.
PMID: 38118405
Rhabdomyosarcoma (RMS) is the main form of pediatric soft-tissue sarcoma. Its cure rate has not notably improved in the last 20 years following relapse, and the lack of reliable preclinical...
10.
Coz E, Fauvernier M, Maucort-Boulch D
Drug Saf
. 2023 Nov;
47(3):205-216.
PMID: 38007401
Over the last few years, several review articles described the adverse events analysis as sub-optimal in clinical trials. Indeed, the context surrounding adverse events analyses often imply an overwhelming number...